Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis

Molecular Pharmacology

Volumn 80, Issue 4, 2011, Pages 683-693

  Phuan, Puay Wah ^a   Yang, Baoxue ^a   Knapp, John M ^b   Wood, Alex B ^b   Lukacs, Gergely L ^c   Kurth, Mark J ^b   Verkman, Alan S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2 AMINOETHYL)AMINO] 5,7 DIMETHYLQUINOLINE 3 CARBONITRILE; 2 CHLORO 5,7 DIMETHYLQUINOLINE 3 CARBALDEHYDE; BENZAMIDE; CHLORIDE CHANNEL; FLAVONE; GENISTEIN; N (3,5 DIMETHYLPHENYL)ACETAMIDE; N [2[(3 CYANO 5,7 DIMETHYLQUINOLIN 2 YL)AMINO]ETHYL] 3 METHOXYBENZAMIDE; QUINOLINE DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASSAY; CYSTIC FIBROSIS; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; RAT; SCREENING; WILD TYPE;

ANIMALS; CELL LINE; CHLORIDE CHANNELS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MUTATION; PHENYLALANINE; PROTEIN FOLDING; QUINOLINES; RATS; RATS, INBRED F344; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053179441     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.073056     Document Type: Article

References (39)

1. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, and Ramsey BW (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363:1991-2003.
2. Branch CL, Coulton S, Johns A, Johnson CN, Porter RA, Stemp G, Thewlis K (2002), inventors; SmithKline Beecham PLC, Branch CL, Coulton S, Johns A, Johnson CN, Porter RA, Stemp G, and Thewlis K, assignees. Preparation of N-aroyl cyclic amines as orexin antagonists. World patent WO2002090355A1. 2002 Nov 14.
3. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, and Smith AE. (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63:827-834. (Pubitemid 120035055)
4. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP, and Lazdunski M (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354:526-528. (Pubitemid 21896832)
5. Du K and Lukacs GL (2009) Cooperative assembly and misfolding of CFTR domains in vivo. Mol Biol Cell 20:1903-1915.
6. Gahman TC, Lang H, Davis RL, Scranton SA (2006), inventors; Kalypsys Inc., Gahman TC, Lang H, Davis RL, and Scranton SA, assignees. Nitrogen-containing heterocyclic compounds as inhibitors of B-Raf kinase. World patent WO2006124874A2. 2006 Nov 23.
7. Grove DE, Rosser MF, Ren HY, Naren AP, and Cyr DM (2009) Mechanisms for rescue of correctable folding defects in CFTR ΔF508. Mol Biol Cell 20:4059-4069.
8. Jurkuvenaite A, Chen L, Bartoszewski R, Goldstein R, Bebok Z, Matalon S, and Collawn JF (2010) Functional stability of rescued ΔF508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am J Respir Cell Mol Biol 42:363-372.
9. Kalid O, Mense M, Fischman S, Shitrit A, Bihler H, Ben-Zeev E, Schutz N, Pedemonte N, Thomas PJ, Bridges RJ, Wetmore DR, Marantz Y, and Senderowitz H (2010) Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des 24:971-991.
10. Kelleher JA (2007), inventor; Neuronascent Inc. and Kelleher JA, assignees. Methods and compositions using heterocyclic compounds for stimulating neurogenesis and inhibiting neuronal degeneration, and therapeutic use. World patent WO2007035722A2. 2007 Mar 29.
11. Kim Chiaw P, Wellhauser L, Huan LJ, Ramjeesingh M, and Bear CE (2010) A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 78:411-418.
12. Kosakata N, Takizawa T, Uchida S, Ono T, and Nakazato Y (2005) inventors; Kyowa Hakko Kogyo Co Ltd., assignee. Preparation of quinoline derivatives, pharmaceuticals and adenosine A2A receptor antagonists containing them, and their use. Japan patent JP2005132834. 2005 May 26.
13. Loo TW, Bartlett MC, and Clarke DM (2008) Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem J 413:29-36. (Pubitemid 351946859)
14. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, and Grinstein S (1994) Conformational maturation of CFTR but not its mutant counterpart (ΔF508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 13:6076-6086.
15. Mills AD, Yoo C, Butler JD, Yang B, Verkman AS, and Kurth MJ (2010) Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein ΔF508-CFTR. Bioorg Med Chem Lett 20:87-91.
16. Moussaoui F, Belfaitah A, Debache A, and Rhouati S (2002) Synthesis and characterization of some new aryl quinolyl αβ-unsaturated ketones. J Soc Alger Chim 12:71-75.
17. Noël S, Wilke M, Bot AG, De Jonge HR, and Becq F (2008) Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 325:1016-1023.
18. Okiyoneda T, Barrière H, Bagdány M, Rabeh WM, Du K, Höhfeld J, Young JC, and Lukacs GL (2010) Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329:805-810.
19. Pedemonte N, Boido D, Moran O, Giampieri M, Mazzei M, Ravazzolo R, and Galietta LJ (2007) Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel. Mol Pharmacol 72:197-207. (Pubitemid 46998539)
20. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, and Verkman AS (2005a) Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115:2564-2571. (Pubitemid 41266219)
21. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, Robins LI, Dicus CW, Willenbring D, Nantz MH, Kurth MJ, Galietta LJ, and Verkman AS (2005b) Phenylglycine and sulfonamide correctors of defective ΔF508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 67:1797-1807. (Pubitemid 40594181)
22. Pedemonte N, Tomati V, Sondo E, Caci E, Millo E, Armirotti A, Damonte G, Zegarra-Moran O, and Galietta LJ (2011) Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. J Biol Chem 286:15215-15226.
23. Pedemonte N, Tomati V, Sondo E, and Galietta LJ (2010) Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol 298:C866-C874.
24. Powers ET, Morimoto RI, Dillin A, Kelly JW, and Balch WE (2009) Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 78:959-991.
25. Riordan JR (2008) CFTR function and prospects for therapy. Annu Rev Biochem 77:701-726.
26. Robert R, Carlile GW, Liao J, Balghi H, Lesimple P, Liu N, Kus B, Rotin D, Wilke M, De Jonge HR, Scholte BJ, Thomas DY, and Hanrahan JW (2010) Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol 77:922-930.
27. Robert R, Carlile GW, Pavel C, Liu N, Anjos SM, Liao J, Luo Y, Zhang D, Thomas DY, and Hanrahan JW (2008) Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 73:478-489. (Pubitemid 351159218)
28. Sampson HM, Robert R, Liao J, Matthes E, Carlile GW, Hanrahan JW, and Thomas DY (2011) Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol 18:231-242.
29. Thibodeau PH, Richardson JM 3rd, Wang W, Millen L, Watson J, Mendoza JL, Du K, Fischman S, Senderowitz H, Lukacs GL, Kirk K, and Thomas PJ (2010) The cystic fibrosis-causing mutation ΔF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem 285:35825-35835.
30. van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, and Negulescu P (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106:18825-18830.
31. van Goor F, Hadida S, Grootenhuis PD, Stack JH, Burton B, Olson E, Wine J, Frizzell RA, Ashlock M, and Negulescu P (2010) Rescue of the protein folding defect in cystic fibrosis in vitro by the investigational small molecule, VX-809. J Cyst Fibros 9 (Suppl 1):S14.
32. van Goor F, Straley KS, Cao D, González J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH, Tung R, Grootenhuis PD, and Negulescu P (2006) Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290:L1117-L1130. (Pubitemid 43830856)
33. Verkman AS and Galietta LJ (2009) Chloride channels as drug targets. Nat Rev Drug Discov 8:153-171.
34. Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H, Riordan JR, Kelly JW, Yates JR 3rd, and Balch WE (2006a) Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127:803-815. (Pubitemid 44716255)
35. Wang Y, Bartlett MC, Loo TW, and Clarke DM (2006b) Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70:297-302.
36. Wellhauser L, Kim Chiaw P, Pasyk S, Li C, Ramjeesingh M, and Bear CE (2009) A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability. Mol Pharmacol 75:1430-1438.
37. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, Galietta LJ, and Verkman AS (2003) Nanomolar affinity small molecule correctors of defective ΔF508-CFTR chloride channel gating. J Biol Chem 278:35079-35085. (Pubitemid 37102270)
38. Ye L, Knapp JM, Sangwung P, Fettinger JC, Verkman AS, and Kurth MJ (2010) Pyrazolylthiazole as ΔF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles. J Med Chem 53:3772-3781.
39. Yu GJ, Yoo CL, Yang B, Lodewyk MW, Meng L, El-Idreesy TT, Fettinger JC, Tantillo DJ, Verkman AS, and Kurth MJ (2008) Potent s-cis-locked bithiazole correctors of ΔF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. J Med Chem 51:6044-6054.